ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

North American Results from the Multicenter Randomized Trial of Everolimus vs Mycophenolate Mofetil in Heart Transplantation

J. Kobashigawa, D. Pauly, H. Ross, A. Kfoury, A. Van Bakel, D. Patel, A. Wiland, P. Lopez, A. Balfour, R. Starling, H. Eisen

Cedars-Sinai Heart Institute, CA
University of Florida College of Medicine, FL
Toronto General Hospital, Toronto, Canada
Intermountain Medical Center, UT
Medical University of South Carolina, SC
Novartis Pharmaceuticals Corp, NJ
Novartis Pharma AG, Basel, Switzerland
Cleveland Clinic, OH
Drexel University College of Medicine, PA

Meeting: 2013 American Transplant Congress

Abstract number: 203

Related Abstracts
  • Superior Renal Function Sustained for 24 Months through Early Everolimus-Facilitated Reduction of Tacrolimus Versus Standard Tacrolimus in De Novo Liver Transplant Recipients: Results of a Randomized Trial
  • Effects of Everolimus and Tacrolimus Exposure on Efficacy and Renal Function in Liver Transplant Recipients at 24 Months in a Randomized Trial (H2304)

Purpose: 24-month (M) results of a randomized, open-label, multinational study (A2310) comparing efficacy and safety of everolimus (EVR) and mycophenolate mofetil (MMF) in de novo heart transplant recipients (HTxR) are available. HTxR in North America (NA) compared to Overall (OVR) had increased diabetes, hypertension, hyperlipidemia, high body mass index; greater ventricular assist device use and less induction therapy. We examined efficacy and adverse events (AEs) for NA HTxR in the A2310 study.

Methods: HTxR were randomized to 1.5mg (N=155) vs 3mg/day (N=99) EVR (goal C0: 3-8 or 6-12ng/mL) w/reduced-dose cyclosporine (rdCsA) or 3g/day MMF w/standard-dose CsA (sdCsA) (N=157) + steroids. The EVR 3mg arm was prematurely terminated due to high mortality. The 24M analysis assessed composite efficacy failure (CEF) and AEs.

Results: 48% NA HTxR (vs. 34% OVR) did not receive induction; and 17% NA (vs. 29% OVR) received thymoglobulin. In all HTxR at 24M, EVR 1.5mg was comparable to MMF for CEF, but inferior for renal function (Table). The incidence of AEs was lower in NA HTxR (EVR/MMF) vs OVR HTxR: neutropenia (5.3%/8.3% vs 17.9%/40.3%); hyperlipidemia (11.8%/5.8% vs 37.3%/26.9%); edema (48.7%/47.4% vs 57.7%/57.1%) & CMV infection (5.3%/16.0% vs 7.2%/21.6%).

Efficacy and renal function at 24M for NA patients
Parameter, n (%) EVR 1.5mg (N=155) MMF (N=157)
Composite efficacy failure (CEF) 54 (34.8)* 65 (41.4)
Acute rejection with hemodyamic compromise 8 (5.2) 10 (6.4)
BPAR ≥ 3a (2R) 38 (24.5) 46 (29.3)
Death 12 (7.7) 12 (7.6)
Graft loss/re-transplant 3 (1.9) 4 (2.5)
Loss to follow-up 3 (1.9) 8 (5.1)
Mean eGFR (MDRD), mL/min/1.73² 58.7** 65.3
*p<0.001; **p=0.166 for comparability to MMF

Conclusion: Despite differences in baseline demographics in NA HTxR, especially less frequent induction, de novo use of EVR 1.5mg + rdCsA has comparable efficacy to MMF + sdCsA. EVR 1.5mg or MMF was better tolerated in NA HTxR vs the OVR population, perhaps due to differences in induction therapy.

Kobashigawa, J.: Grant/Research Support, Novartis Pharmaceuticals, Other, Novartis Pharmaceuticals, Data Safety Monitoring Board. Pauly, D.: Grant/Research Support, Novartis Pharmaceuticals. Ross, H.: Other, Novartis Pharmaceuticals, Principal Investigator. Kfoury, A.: Grant/Research Support, Novartis Pharmaceuticals. Van Bakel, A.: Grant/Research Support, Novartis Pharmaceuticals. Patel, D.: Employee, Novartis. Wiland, A.: Employee, Novartis. Lopez, P.: Employee, Novartis. Balfour, A.: Employee, Novartis. Starling, R.: Grant/Research Support, Novartis. Eisen, H.: Grant/Research Support, Novartis.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kobashigawa J, Pauly D, Ross H, Kfoury A, Bakel AVan, Patel D, Wiland A, Lopez P, Balfour A, Starling R, Eisen H. North American Results from the Multicenter Randomized Trial of Everolimus vs Mycophenolate Mofetil in Heart Transplantation [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/north-american-results-from-the-multicenter-randomized-trial-of-everolimus-vs-mycophenolate-mofetil-in-heart-transplantation/. Accessed February 26, 2021.

« Back to 2013 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Left-Sided Donor Nephrectomy Predisposes Living Kidney Donors to Latent Adrenal Insufficiency with Symptoms of Fatigue and Inferior Quality of Life.
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.